• Eli Lilly and Co., of Indianapolis, said it is stopping ongoing trials testing promaglumetad methionil, also known as mGlu2/3, for the treatment of schizophrenia, after a recently conducted independent futility analysis concluded that the second of two pivotal studies was unlikely to be positive in its primary efficacy endpoint if enrolled to completion.